New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.'s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for presbyopia in adults.

Benzinga • Jan 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jan 22, 2026

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

GlobeNewsWire • Jan 14, 2026

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Launched VIZZ™  (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

GlobeNewsWire • Jan 7, 2026

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.

GlobeNewsWire • Jan 5, 2026

LENZ Therapeutics: Was That A Market Overreaction?

LENZ Therapeutics, Inc. shares fell ~30% after a reported adverse event with VIZZ, but I do not view this as thesis-destroying. VIZZ offers superior efficacy and duration versus competitors, yet faces potentially slow market adoption and entrenched alternatives like glasses, contacts, and LASIK. LENZ's $3 billion market opportunity is plausible but hinges on shifting consumer behavior and overcoming negative sentiment from recent safety news.

Seeking Alpha • Dec 17, 2025

LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 4, 2025

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ

GlobeNewsWire • Dec 1, 2025

LENZ Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:

GlobeNewsWire • Nov 25, 2025

LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript

LENZ Therapeutics, Inc. ( LENZ ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Daniel Chevallard - Chief Financial Officer Evert Schimmelpennink - President, CEO, Secretary & Director Shawn Olsson - Chief Commercial Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Biren Amin - Piper Sandler & Co., Research Division Marc Goodman - Leerink Partners LLC, Research Division Pavan Patel - BofA Securities, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Matthew Caufield - H.C.

Seeking Alpha • Nov 5, 2025